Fox Chase Cancer Center News

PHILADELPHIA (February 13, 2025) — Fox Chase Cancer Center is pleased to announce the hiring of Michael Noonan, DO, MS, as an Assistant Professor in the Supportive Oncology and Palliative Care Program.

PHILADELPHIA (February 10, 2024) — Jeffrey Farma, MD, FACS, Chair of the Department of Surgery at Fox Chase Cancer Center, and a team of colleagues recently published an updated review of guidelines governing the use of neoadjuvant and adjuvant therapy for patients with melanoma.

PHILADELPHIA (January 31, 2025) — Parth A. Desai, MBBS, MD, Assistant Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently awarded the 2024 Innovation Award by Ride Hard Breathe Easy, which helps raise awareness and funds for patients being treated for lung cancer.

PHILADELPHIA (January 31, 2025) — Lilian J. Shin-Cho, PhD, an Assistant Professor in the Cancer Prevention and Control Research Program at Fox Chase Cancer Center, was recently selected as an American Psychosocial Oncology Society (APOS) 2025 Health Equity Scholar.

PHILADELPHIA (January 31, 2025) — Eric Goodlev, MD, an Associate Professor in the Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center, was recently named a Fellow of the American Academy of Hospice and Palliative Medicine (AAHPM).

PHILADELPHIA (January 29, 2025) — Austin D. Williams, MD, MSEd, FACS, Assistant Professor in the Division of Breast Surgery within the Department of Surgery at Fox Chase Cancer Center, was recently named a Presidential Scholar by the Society of Surgical Oncology (SSO).

PHILADELPHIA (January 29, 2025) — Emma Guilbaud, PhD, a postdoctoral associate at Fox Chase Cancer Center, has been selected as a Forbeck Scholar by the William Guy Forbeck Research Foundation. This prestigious appointment recognizes early career cancer researchers for their achievements, research, and dedication to the field.

PHILADELPHIA (January 24, 2025) — The number of patients receiving immune checkpoint inhibitors and PD-L1 testing for treatment of gastroesophageal cancer (GEC) increased following Food and Drug Administration (FDA) approval, according to a new study presented by researchers at Fox Chase Cancer Center.